retatrutide dosing clinical trials retatrutide dose Guide: 1-12 mg Weekly Triple Agonist (2026) retatrutide dose study trial doses

Resources: GLP-1 Agonists Dual GIP and GLP-1 Receptor Agonist Tirzepatide Improves Beta-cell Function and Insulin Sensitivity in Type 2 Diabetes Safety of Semaglutide Once-Weekly Semaglutide in Adults with Overweight or Obesity Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity Medication-Induced Gastroparesis: A Case Report Comparison of tirzepatide and dulaglutide on major adverse cardiovascular events in participants with type 2 diabetes and atherosclerotic cardiovascular disease: SURPASSCVOT design and baseline characteristics Tirzepatide for the treatment of obstructive sleep apnea: Rationale, design, and sample baseline characteristics of the SURMOUNT -OSA phase 3 trial Tirzepatide prevents neurodegeneration through multiple molecular pathways TripleHormone-Receptor Agonist Retatrutide for Obesity A Phase 2 Trial Biology of Incretins: GLP-1 and GIP GIP and GLP1, the two incretin hormones: Similarities and differences GLP-1, GIP and glucagon receptor poly-agonists: A new era in obesity pharmacotherapy

Kwon, J., Thiara, D., & Watanabe, J

Retatrutide side effects appear to be dose-related, with higher doses generally linked to more frequent or noticeable symptoms

Skeletal muscle deoxygenation after the onset of moderate exercise suggests slowed microvascular blood flow kinetics in type 2 diabetes